Examining Current Perspectives in Psoriasis Management: Patient and Provider Insights to Optimize Care

Activity Details
  • Credit Amounts:
  • Cost: Free
  • Release: Jan 31, 2017
  • Expires: Jan 31, 2018
  • Average User Rating:
    ( Ratings)

To Complete Activity Click Here



B. Jang Johnson B. Jang Johnson, PA-C
Lakeview Dermatology
Chicago, IL

Neil Korman Neil Korman, MD, PhD
Director, Clinical Trials Unit, UH Cleveland Medical Center
Director, Murdough Family Center for Psoriasis
UH Cleveland Medical Center
Professor, Dermatology, CWRU School of Medicine
Cleveland, OH

Melodie Young Melodie Young, MSN, RN, ANP-C
Nurse Practitioner
Modern Dermatology-Aesthetics Center
Baylor Health Care System
Dallas, TX

Needs Statement

Uncontrolled psoriatic disease significantly impacts the quality of life of those affected resulting in depression, anxiety, and social distress due to the physical burden of the disease. As the understanding and treatment of psoriasis has changed significantly in recent years, it is critical that clinicians who manage this disease have a thorough understanding of the disease and treatment options available. The goal of this educational activity is to provide Dermatology Physicians, Physician Assistants (PAs), Nurses, Nurse Practitioners (NPs), and other members of the psoriasis care team with an understanding of the patient’s perspective of disease severity and treatment success to enable clinicians to better design treatment plans to improve both clinical outcomes and patient quality of life. To help clinicians truly understand the patient’s view of psoriatic disease, patient ambassadors from the National Psoriasis Foundation will share their personal stories and insights regarding the day-to-day struggles of living with psoriasis.

Target Audience

Dermatologists, nurse practitioners, nurses, physician assistants, and other healthcare professionals who treat patients with psoriasis.


  1. Assess quality of life in patients with psoriasis including factors such as social burden, intimacy, relationships, employment, workplace productivity, and comorbid psychiatric conditions.
  2. Discuss disease severity and treatment satisfaction with patients who have psoriasis in order to eliminate discrepancies between clinician views of psoriatic disease, goals of treatment, and the opinions of the patient.
  3. Design individualized treatment plans for patients with psoriasis using clinical safety and efficacy data that take into account quality of life and the patient’s perspectives on disease severity and measures of treatment success.

Faculty Disclosure

In accordance with the Food and Drug Administration, the faculty have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in educational presentations. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


Adrienne Matson, PharmD has no financial relationships to disclose in relation to the content of this activity.

Peer Reviewer(s):

David Pariser, MDhas disclosed that he receives grant/research funding from LEOPharmaInc., Abbott Laboratories, Amgen, Bickel Biotechnology, Celgene, Lilly, Novartis, Novo Nordisk, Ortho Dermatologies, Photocure ASA, Promius Pharmaceuticals, Regeneron, Stiefel a GSK company, and Valeant Pharmaceuticals International. He receives honoraria from Bickel Biotechnology, Biofrontera AG, Celgene, Dermira, DUSA Pharmaceuticals, LEO Pharma US, Novartis, Pfizer, Promius Pharmaceuticals, Regeneron, TheraVida, and Valeant Pharmaceuticals International.

Kristine Kucera, PA-C, MPAS, DHS has no financial relationships to disclose in relation to the content of this activity.

Todd Martin, ARNP has no financial relationships to disclose in relation to the content of this activity.


B. Jang Mi Johnson, PA-C has disclosed that she is a consultant for Taro Pharma and is a member of the speaker’s bureaus for Galderma and Aqua Pharma.

Neil J. Korman, MD has disclosed that he is a consultant for Novartis and Pfizer; receives grant/research support from Abbvie, Amgen, Celgene, Chugai, Lilly, Janssen, Kyowa, Merck, Regeneron, and Trevi. He is also a member of the speakers’ bureaus for Abbvie, Celgene, Lilly, Janssen, and Novartis.

Melodie S. Young, RN, ANP-C has disclosed that she is a consultant for Abbvie, Celgene, Lilly, and Novartis; receives grant/research support from Boehringer Ingelheim, Celgene, Dermira, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Regeneron, UCB, and Valeant. She is also a member of the speakers’ bureaus for Abbvie, Celgene, Janssen, and Lilly.


This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.